404 related articles for article (PubMed ID: 35499469)
1. "The idea is to help people achieve greater success and liberty": A qualitative study of expanded methadone take-home access in opioid use disorder treatment.
Suen LW; Castellanos S; Joshi N; Satterwhite S; Knight KR
Subst Abus; 2022; 43(1):1143-1150. PubMed ID: 35499469
[No Abstract] [Full Text] [Related]
2. Rural opioid treatment program patient perspectives on take-home methadone policy changes during COVID-19: a qualitative thematic analysis.
Levander XA; Hoffman KA; McIlveen JW; McCarty D; Terashima JP; Korthuis PT
Addict Sci Clin Pract; 2021 Dec; 16(1):72. PubMed ID: 34895346
[TBL] [Abstract][Full Text] [Related]
3. Changes in methadone program practices and fatal methadone overdose rates in Connecticut during COVID-19.
Brothers S; Viera A; Heimer R
J Subst Abuse Treat; 2021 Dec; 131():108449. PubMed ID: 34098303
[TBL] [Abstract][Full Text] [Related]
4. Lessons from the First Wave of COVID-19 for Improved Medications for Opioid Use Disorder (MOUD) Treatment: Benefits of Easier Access, Extended Take Homes, and New Delivery Modalities.
Walters SM; Perlman DC; Guarino H; Mateu-Gelabert P; Frank D
Subst Use Misuse; 2022; 57(7):1144-1153. PubMed ID: 35443862
[No Abstract] [Full Text] [Related]
5. "It didn't hurt me": patients' and providers' perspectives on unsupervised take-home doses, drug diversion, and overdose risks in the provision of medication for opioid use disorder during COVID-19 in San Juan, Puerto Rico.
Abadie R; Fisher CB
Harm Reduct J; 2024 Apr; 21(1):85. PubMed ID: 38664796
[TBL] [Abstract][Full Text] [Related]
6. Patient experiences of COVID-19-induced changes to methadone treatment in a large community-based opioid treatment program in Baltimore.
Abidogun TM; Cole TO; Massey E; Kleinman M; Greenblatt AD; Seitz-Brown CJ; Magidson JF; Belcher AM
J Subst Use Addict Treat; 2023 Feb; 145():208946. PubMed ID: 36880915
[TBL] [Abstract][Full Text] [Related]
7. COVID-19-related policy changes for methadone take-home dosing: A multistate survey of opioid treatment program leadership.
Levander XA; Pytell JD; Stoller KB; Korthuis PT; Chander G
Subst Abus; 2022; 43(1):633-639. PubMed ID: 34666636
[No Abstract] [Full Text] [Related]
8. Utilization of Medications for Opioid Use Disorder Across US States: Relationship to Treatment Availability and Overdose Mortality.
Krawczyk N; Jent V; Hadland SE; Cerdá M
J Addict Med; 2022 Jan-Feb 01; 16(1):114-117. PubMed ID: 35120067
[TBL] [Abstract][Full Text] [Related]
9. "No home to take methadone to": Experiences with addiction services during the COVID-19 pandemic among survivors of opioid overdose in Boston.
Harris MTH; Lambert AM; Maschke AD; Bagley SM; Walley AY; Gunn CM
J Subst Abuse Treat; 2022 Apr; 135():108655. PubMed ID: 34772604
[TBL] [Abstract][Full Text] [Related]
10. Shifting Medication Treatment Practices in the COVID-19 Pandemic: A Statewide Survey of Pennsylvania Opioid Treatment Programs.
Krawczyk N; Maniates H; Hulsey E; Smith JS; DiDomenico E; Stuart EA; Saloner B; Bandara S
J Addict Med; 2022 Nov-Dec 01; 16(6):645-652. PubMed ID: 35165225
[TBL] [Abstract][Full Text] [Related]
11. Unprecedented need and recommendations for harnessing data to guide future policy and practice for opioid use disorder treatment following COVID-19.
Livingston NA; Ameral V; Banducci AN; Weisberg RB
J Subst Abuse Treat; 2021 Mar; 122():108222. PubMed ID: 33303255
[TBL] [Abstract][Full Text] [Related]
12. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
[TBL] [Abstract][Full Text] [Related]
13. Reimagining patient-centered care in opioid treatment programs: Lessons from the Bronx during COVID-19.
Joseph G; Torres-Lockhart K; Stein MR; Mund PA; Nahvi S
J Subst Abuse Treat; 2021 Mar; 122():108219. PubMed ID: 33353790
[TBL] [Abstract][Full Text] [Related]
14. Adoption of methadone take home policy by U.S. state opioid treatment authorities during COVID-19.
Roy V; Buonora M; Simon C; Dooling B; Joudrey P
Int J Drug Policy; 2024 Feb; 124():104302. PubMed ID: 38183861
[TBL] [Abstract][Full Text] [Related]
15. The impact of COVID-19 and rapid policy exemptions expanding on access to medication for opioid use disorder (MOUD): A nationwide Veterans Health Administration cohort study.
Livingston NA; Davenport M; Head M; Henke R; LeBeau LS; Gibson TB; Banducci AN; Sarpong A; Jayanthi S; Roth C; Camacho-Cook J; Meng F; Hyde J; Mulvaney-Day N; White M; Chen DC; Stein MD; Weisberg R
Drug Alcohol Depend; 2022 Dec; 241():109678. PubMed ID: 36368167
[TBL] [Abstract][Full Text] [Related]
16. Nothing really changed: Arizona patient experience of methadone and buprenorphine access during COVID.
Meyerson BE; Bentele KG; Russell DM; Brady BR; Downer M; Garcia RC; Garnett I; Lutz R; Mahoney A; Samorano S; Arredondo C; Andres HJ; Coles H; Granillo B
PLoS One; 2022; 17(10):e0274094. PubMed ID: 36282806
[TBL] [Abstract][Full Text] [Related]
17. Differences in the delivery of medications for opioid use disorder during hospitalization by racial categories: A retrospective cohort analysis.
Priest KC; King CA; Englander H; Lovejoy TI; McCarty D
Subst Abus; 2022; 43(1):1251-1259. PubMed ID: 35670778
[No Abstract] [Full Text] [Related]
18. Dynamic changes in methadone utilisation for opioid use disorder treatment: a retrospective observational study during the COVID-19 pandemic.
Kennalley AL; Fanelli JL; Furst JA; Mynarski NJ; Jarvis MA; Nichols SD; McCall KL; Piper BJ
BMJ Open; 2023 Nov; 13(11):e074845. PubMed ID: 37973543
[TBL] [Abstract][Full Text] [Related]
19. Impact of COVID-19-related methadone regulatory flexibilities: views of state opioid treatment authorities and program staff.
Mitchell SG; Jester J; Gryczynski J; Whitter M; Fuller D; Halsted C; Schwartz RP
Addict Sci Clin Pract; 2023 Oct; 18(1):61. PubMed ID: 37848970
[TBL] [Abstract][Full Text] [Related]
20. Critical incidents in Colorado's opioid treatment programs: A comparison of the COVID-19 pandemic to previous years.
Bortz C; Armistead I; Bonaguidi A; Coyle DT
J Subst Use Addict Treat; 2024 Jun; 161():209342. PubMed ID: 38513975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
